New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective TreatmentsASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient ...

Partnership will deliver powerful and scalable performance upgrades for GM vehicles and aims for enhanced dealer network accessBOWLING GREEN, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, and Callaway Cars, a premier provider of OEM-integrated performance solutions, today announced a partnership to develop and launch a line of performance packages for GM trucks and SUVs. The partnership marks a new era for two automot ...

12-inch limited-edition figures featuring iconic characters available now at CostcoSUNRISE, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (NASDAQ: AENT), a leading distributor and fulfillment partner of entertainment and pop culture collectibles, today announced the launch of a new limited-edition product line from its Handmade by Robots™ brand —mega-sized, 12-inch vinyl figures featuring iconic horror characters. The launch marks a strategic first-to-market campaign, wi ...

Core Viewpoint - The Marketing Alliance, Inc. reported a strong start to fiscal year 2026, with significant growth in revenues and net income, driven by investments in the insurance distribution and construction businesses [3][6]. Financial Performance - Revenues from operations increased to $4,859,890, up over 9% from $4,458,043 in the prior year quarter [6][7]. - Operating income from continuing operations rose to $250,266 compared to $48,856 in the prior year quarter [6][7]. - Net income for the quarter was $275,624, or $0.04 per share, compared to a net loss of $49,853, or ($0.01) per share, in the prior year quarter [6][7]. Revenue Breakdown - Insurance commission and fee revenue was $4,680,304, up from $4,360,591 [13]. - Construction revenue increased to $179,586 from $97,452 [13]. - Net operating revenue (gross profit) for the quarter was $968,792, compared to $848,631 in the prior year quarter [7][13]. Operating Expenses - Operating expenses decreased to $718,526 from $799,775 in the prior year quarter, despite an increase in compensation expenses [7]. - The company reported an operating EBITDA of $296,612, an increase from $123,607 in the previous year quarter [7][17]. Share Repurchase Program - The Board of Directors authorized a share repurchase program for up to 800,000 shares, effective immediately and concluding March 31, 2026 [6][7]. - As of August 7, 2025, the company had repurchased 200,880 shares under this program [6][7]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents were $2.1 million, with working capital of $5.2 million and shareholders' equity of $5.6 million [12]. - The company repaid a note payable of $1,912,882 in full at its maturity in June 2025 [12].

Core Insights - Branded Legacy, Inc. has completed the acquisition of Bio Legacy Evaluative Group, formerly Menlo Health, which positions the company to address global health challenges and enhance shareholder value through innovative technologies and strategic leadership [1][2][8] - The acquisition is expected to drive significant revenue growth, with projections indicating that Bio Legacy could generate up to $183.3 million in revenues by Year 5 [7] Acquisition Details - The acquisition agreement was executed on July 28, 2025, and closed on July 31, 2025, allowing Bio Legacy to operate as a wholly-owned subsidiary of Branded Legacy [5][8] - The deal involved an all-stock transaction valued at $1.5 million in Preferred D stock, aligning the interests of Bio Legacy with existing shareholders [5] Leadership and Vision - Amin Janmohamed has been appointed as CEO, and Dr. Kristian Thorlund as Chairman, bringing expertise to guide the company through its growth trajectory [3][8] - The leadership team is committed to long-term growth and innovation, focusing on delivering measurable results and substantial returns for shareholders [2][8] Product and Market Potential - Bio Legacy's patented intranasal naloxone device aims to address the addiction crisis, with the market expected to grow from $371 million in 2022 to over $1.16 billion by 2032, reflecting a CAGR of approximately 11.9% [4] - The company plans to expand its product offerings into vaccines and cold-chain therapies, tapping into significant untapped markets [4] Roadmap and Milestones - A robust R&D investment of $1 million is planned post-uplisting to OTCQB, with key milestones including manufacturing prototyping in Q3 2025, full patent filings in Q4 2025, and clinical trials in 2026 [6][5] - The naloxone device is set for market launch in Q1 2027, with expectations of substantial revenue contributions to Branded Legacy's portfolio [7]

Core Insights - ECGI Holdings Inc. is set to enhance its portfolio company, Payday Fantasy, by integrating NFL and NCAA Football data and launching a fantasy sports marketplace, aiming to capitalize on the peak football season for increased user engagement [1][2][3][6] Company Developments - Payday Fantasy will soon go live with NFL and NCAA Football data, allowing users to engage with real-time player and game data [2] - A marketing push is planned to accelerate user growth and enhance market engagement during the football season [4] - The platform aims to combine live data integration with marketplace functionality to attract a growing audience in the fantasy sports sector [5][6] Industry Context - The fantasy sports market in North America has over 60 million participants, with a global market valuation of $24.8 billion in 2024, projected to grow at a 15.2% CAGR, reaching over $56 billion by 2030 [5] - The enhancements to Payday Fantasy's platform are strategically timed to coincide with the NFL preseason and regular season, a period known for increased fantasy sports participation [3][6] Competitive Positioning - Simon Yu, CEO of ECGI Holdings, emphasized that the upcoming enhancements position Payday Fantasy to compete in a multi-billion-dollar industry [6] - The platform aims to transform fantasy sports into a shared experience, leveraging elements from popular platforms like Discord, DraftKings, and Twitch [8]

BOCA RATON, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Vocodia Holdings Corp. (OTC:VHAI), a leading developer of advanced AI-driven voice solutions, has demonstrated its ability to outperform traditional sales teams by helping men’s wellness brand Maxoderm achieve higher revenue per call than its American-based human call center. After evaluating several AI platforms, Maxoderm chose Vocodia for its proven performance in real-world sales environments. The results exceeded expectations, with Vocodia’s digital vo ...

Core Insights - NetraMark Holdings Inc. has appointed Dr. Jan Sedway as Senior Vice President of Clinical Science, enhancing its leadership team in the AI-driven clinical trial sector [1][5] - The company aims to expand its presence in the pharmaceutical industry, particularly in psychiatry and oncology, leveraging its proprietary technology to capture market share in a rapidly growing global market for AI-driven clinical trial optimization [2][6] Company Overview - NetraMark focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [6] - The company's technology allows for effective segmentation of diseases and classification of patients based on drug sensitivity and treatment efficacy, even with smaller datasets [6] Leadership Experience - Dr. Sedway brings over 20 years of experience in clinical research and global operations, having previously held leadership roles at Clario, Parexel, and Syneos Health [3][4] - Her expertise includes advancing digital biomarker solutions and enhancing operational excellence in global clinical trials, aligning with NetraMark's growth strategy [3][5]

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [3] - The company aims to revolutionize portable testing through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [3] - The system is designed to be hygienic and cost-effective, screening for recent drug use including opiates, cocaine, methamphetamine, and cannabis [3] Technology and Applications - The Intelligent Fingerprinting Drug Screening System allows for sample collection in seconds and provides results in under ten minutes [3] - This technology is particularly valuable for employers in safety-critical industries, enhancing workplace safety [3] - Current customer segments outside the US include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [3] Upcoming Events - The management team will participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025 [1] - A presentation is scheduled for August 21, 2025, at 9:15 a.m. Eastern Time [2] - Interested parties can register for the conference through a provided link and schedule one-on-one meetings with the management team [2]

Core Insights - Crypto.com has partnered with VivoPower International PLC to provide custodial support for VivoPower's digital asset treasury and mining strategies, enhancing its digital asset management capabilities [3][6] - VivoPower's shares will be available for trading on Crypto.com's platform, allowing access to its 150 million users, which is expected to improve liquidity for both VivoPower and its digital assets [5][6] Group 1: Partnership Details - VivoPower has selected Crypto.com as a strategic partner for custodial services, focusing on expanding its digital asset treasury holdings and mining strategy [3][4] - Crypto.com Custody will offer an end-to-end solution for eligible institutions and high-net-worth clients, emphasizing safety and security [4][6] Group 2: Market Impact - The partnership will facilitate easier trading of VivoPower's shares for both retail and institutional investors through a secure digital platform [5][6] - Shareholders will benefit from enhanced liquidity for XRP and other digital assets, along with access to upcoming XRP restaking via Flare [5][6] Group 3: Company Background - Crypto.com, founded in 2016, serves over 150 million customers and is recognized for its regulatory compliance and security [7] - VivoPower is transforming into an XRP-focused digital asset enterprise, aiming to support decentralized finance and blockchain applications [8][9]